重组人干扰素α_2b与吡柔比星并用对膀胱肿瘤复发的治疗和预防

Prevention and treatment of the recurrent bladder cancer with recombined human Interferon α2b And THP

目的 :探讨重组人干扰素α2 b与吡柔比星并用对膀胱肿瘤复发的治疗和预防。方法 :采用干扰素α2 b(安达芬 )并吡柔比星 (THP)联合应用膀胱内灌注治疗并预防膀胱肿瘤复发 2 1例 ,并与同期灌注丝裂霉素C19例 ,对照组 15例 ,进行随访观察。结果 :联合用药组肿瘤复发率明显低于比较组和对照组 ( 4 .76%,15 .79%,3 3 .3 %)治疗前后淋巴细胞转化试验平均值联合用药组分别为 5 2 .3 %和 71.7%,P <0 .0 5 ,丝裂霉素治疗前后分别为 5 3 .1%和 5 5 .7%,差异无显著性意义。结论 :干扰素α2 b和吡柔比星联合应用治疗及预防膀胱肿瘤的复发 ,既能达到杀伤癌细胞 ,又能激活免疫细胞的功能 ,近期疗效好。

Objective To study the prevention and treatment of recurrent bladder cancer with recombined human interferon α 2b And THP. Methods Twenty one patients receiving combined human interferon α 2b and THP were compared with 19 patients receiving mitomycin and 15 patients without treatment. Results The recurrent rate of the combined group was obviously lower than the other two groups (4.76%, 15.7% and 33.3%). The average values of the lymphocyte conversion test before and after treatment were 52.3% and 71.7% ( P <0.05) in the first group, 53.1% and 55.7% in mitomycin group ( P >0.05). Conclusion The combined interferon α2b and THP can both kill the cancer cell and activate the immunocyte.The short term effect is satisfactory.